EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control
Katherine Tuttle, André Scheen and Norbert Stefan discuss the benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control at EASD TV during #EASD2023. Are SGLT2 inhibitors and GLP-1 receptor agonists also beneficial for heart, kidney and liver disease? #diabetes #cardiovasculardisease #chronickidneydisease #liverdisease
▶︎
Navigating GLP-1 agonists | DoM Grand Rounds | 17 January 2024
▶︎
Could we change the course of MASLD - what is available and what is in the pipeline?
▶︎
Bladder burnt away by a doctor in Turkey who I found on youtube. Chronic UTI story part 1
▶︎
EASD 2023 - Peter Thorn and Sushil Rane explaining the relationship between diabetes and the brain
▶︎
What are SGLT2 inhibitors and how do they affect kidney disease?
▶︎
2026 Renewable Fuels Summit: Day 3 Opening Address & Low Carbon Liquid Fuels - Why 2026 Matters
▶︎
What are GLP-1 Drugs? A Complete Guide to Understanding GLP-1s
▶︎
SGLT2 Inhibitors and GLP1 Receptor Agonists Reduce All-Cause Mortality Among Other Patient Benefits
▶︎
EASD 2025: Towards arresting type 1 diabetes - Breaking results of the MELD-ATG & Ver-A-T1D trials
▶︎
Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists
▶︎
EASD 2025: Care for Women with Pre-Existing Diabetes During Pregnancy
▶︎
Basic Mechanisms of SGLT2 inhibitors in the Kidney
▶︎
Metabologia – Introducing EASD's New Journal
▶︎
GLP-1 Agonists: Wonder Drugs of the 21st Century?
▶︎
Cum ne îmbolnăvește mâncarea | BOABE DE CUNOAȘTERE | cu dr. Mihai Diculescu
▶︎
Guías Diabetes ADA 2024 . ¿Qué hay de nuevo? (Standards of Care in Diabetes 2024)
▶︎
Col. Douglas Macgregor: Dire Warning On The War In Iran
▶︎
Cardiovascular Benefits of GLP-1 RAs
▶︎
Type 2 Diabetes: Best & Safest Medications for Older Adults
▶︎